Stay updated with breaking news from Nasdaq Prld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,130,000 shares, a decline of 20.5% from the July 15th total of 2,680,000 shares. Based on an average trading volume of 121,300 shares, the days-to-cover ratio […]
Prelude Therapeutics (NASDAQ:PRLD – Free Report) had its target price reduced by Barclays from $7.00 to $5.00 in a research note released on Friday, Marketbeat Ratings reports. They currently have an equal weight rating on the stock. Prelude Therapeutics Stock Performance Shares of Prelude Therapeutics stock opened at $3.67 on Friday. Prelude Therapeutics has a […]
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) Director Orbimed Advisors Llc acquired 869,565 shares of the firm’s stock in a transaction on Monday, May 22nd. The stock was purchased at an average cost of $5.75 per share, with a total value of $4,999,998.75. Following the purchase, the director now owns 10,119,756 shares of the company’s […]
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) Director Orbimed Advisors Llc acquired 869,565 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was bought at an average price of $5.75 per share, for a total transaction of $4,999,998.75. Following the purchase, the director now owns 10,119,756 shares in the company, […]
WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage...